Lonza Group Overview

  • Founded

  • 1897

Founded
  • Status

  • Public

  • Employees

  • 17,154

Employees
  • Stock Symbol

  • LONN

Stock Symbol
  • Investments

  • 42

  • Share Price

  • $585.44

  • (As of Wednesday Closing)

Lonza Group General Information

Description

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Contact Information

Website
www.lonza.com
Formerly Known As
Lonza AG Electricity Works
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
SWX
Primary Office
  • Muenchensteinerstrasse 38
  • 4002 Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lonza Group Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$585.44 $576.93 $445.25 - $740.21 $43.4B 186K $45.03

Lonza Group Financials Summary

In Thousands,
USD 		TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 39,172,554 65,385,522 51,841,178 30,589,235
Revenue 6,274,135 5,916,390 4,800,801 4,233,630
EBITDA 1,209,989 1,483,199 1,487,737 1,329,362
Net Income 3,343,560 3,220,161 925,443 649,083
Total Assets 17,543,878 18,005,689 16,515,200 14,284,830
Total Debt 2,517,944 3,007,330 4,365,443 3,905,339
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lonza Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lonza Group‘s full profile, request access.

Request a free trial

Lonza Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small mo
Biotechnology
Basel, Switzerland
17,154 As of 2022
00000
0.000 0000-00-00
00000000000 00000

000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pr
0000 00000000
Somerset, NJ
00000 As of 0000
00.000
000000&0

000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
000000000000000
Plankstadt, Germany
0000 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lonza Group Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Catalent Formerly PE-Backed Somerset, NJ 00000 00.000 000000&0
000000000000 Private Equity-Backed Plankstadt, Germany 0000 000000000000
00000 Corporation Basel, Switzerland 000000 00.000 00000000000 00.000
000000000 00000000 Formerly PE-Backed Oklahoma City, OK 000 0000 000000&0 0000
000000000 000000 Corporation Hyderabad, India 00000 00000 000000000 00000
You’re viewing 5 of 35 competitors. Get the full list »

Lonza Group Patents

  • 6,591

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 189

    Granted

  • 106

    Pending

  • 000

    Expiring in next 12 mo

Lonza Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3191188-A1 Device for providing a cell suspension Pending 06-Oct-2020 000000000
EP-3981867-A1 Device for providing a cell suspension Pending 06-Oct-2020 000000000 0
CA-3187792-A1 Microbial culture medium Pending 01-Jul-2020 00000000
EP-4127185-A1 Helper factors for expressing proteins in yeast Pending 01-Apr-2020 000000000
US-20230038151-A1 Methods of determining viral titer Pending 28-Jan-2020 C12Q1/701
To view Lonza Group’s complete patent history, request access »

Lonza Group Executive Team (33)

Name Title Board Seat Contact Info
Pierre-Alain Ruffieux Ph.D Chief Executive Officer & Member of the Executive Committee
Philippe Deecke Chief Financial Officer & Member of the Executive Committee
Caroline Barth Chief Human Resources Officer & Member of the Executive Committee
Donald Sohn Associate Director, M&A
Bernhard Mayer Director of Mergers & Acquisitions and Corporate Development
You’re viewing 5 of 33 executive team members. Get the full list »

Lonza Group Board Members (9)

Name Representing Role Since
000000 000000 Lonza Group Chairman & Board Member 000 0000
0000000 00000000 Self Board Member 000 0000
00000000 00000 Lonza Group Chief Human Resources Officer & Member of the Executive Committee 000 0000
00000000 0000000 Self Board Member 000 0000
0000000 0000000000 Lonza Group Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Lonza Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lonza Group Investments & Acquisitions (42)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 10-Feb-2022 00000 0000 0000 Drug Discovery
000000 000000 15-Nov-2021 000000000 0000 Buildings and Property 0000000 0
000000000 (00 02-Nov-2021 0000000000 Biotechnology 0000000 0
0000000 00000 03-May-2021 00000 0000 00000 Drug Discovery
Affinia Therapeutics 12-Mar-2020 Early Stage VC 0000 Drug Discovery
You’re viewing 5 of 42 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Lonza Group Subsidiaries (7)

Company Name Industry Location Founded
Vivante GMP Solutions Other Pharmaceuticals and Biotechnology Houston, TX 2009
000000 0000000 Biotechnology Kingston, Canada 0000
00000000000 0000 0 Clinics/Outpatient Services Tallinn, Estonia 0000
000000 Biotechnology Munster, Germany 0000
00000 Biotechnology Cologne, Germany 0000
You’re viewing 5 of 7 subsidiaries. Get the full list »

Lonza Group ESG

Risk Overview

Risk Rating

Updated September, 04, 2022

16.43 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,231

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 899

Rank

0.00

Percentile

Laboratory Equipment and Services

Subindustry

00 of 67

Rank

00.0

Percentile

To view Lonza Group’s complete esg history, request access »

Lonza Group Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 13-Nov-2017 0000 00000 00.000 Completed
  • 5 buyers
0000000000000 02-Dec-2016 00000 00000 00 000 Completed
  • 4 buyers
0000000 00000 14-Feb-2013 00000 00000 00 00.00 Completed
  • 3 buyers
0000000 00000 17-Mar-2010 00000 00000 00 00.00 Completed
  • 00000 00000
Cutanogen 02-Feb-2006 Merger/Acquisition 00.00 Completed
You’re viewing 5 of 6 exits. Get the full list »